secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122816
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q3 net loss $19.2M; cash runway to end 2026; Phase 2 enrollment on track
--------------------------------------------------------------------------------

- Net loss $19.2M in Q3 2024 vs $16.6M Q3 2023; R&D spend rose to $16.9M on trial costs.
- Cash $197.9M at Sep 30, 2024; provides expected runway to end of 2026.
- Phase 2 PYNNACLE trial enrollment on track; >75% sites activated; interim analysis expected mid-2025.
- Investigator-initiated Phase 1b of rezatapopt in AML/MDS with MD Anderson and MSKCC; enrollment planned Q1 2025.
- Discontinued Phase 1b combination arm with pembrolizumab due to dose-limiting toxicities and limited benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017024122816/0000950170-24-122816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017024122816/pmvp-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer